There is abundant precedent for targeting IL-6 or its soluble receptor to ablate pathologic cytokine release cascades associated with rheumatoid arthritis (51), adoptive immunotherapy (52), or infectious disease and sepsis (53, 54). This evidence concerns the gene IL6 and infectious disease.